These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30639044)

  • 1. [Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].
    Chazot C; Fadel B; Kareche M; Puyoo O; Jean G
    Nephrol Ther; 2019 Mar; 15(1):29-34. PubMed ID: 30639044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
    Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
    BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?].
    Bataille P; Delattre V; Daroux M
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S103-S108. PubMed ID: 28577730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Floege J
    Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Lioulios G; Stangou M; Sarafidis PA; Tsouchnikas I; Minasidis I; Vainas A; Faitatzidou D; Sampani E; Papagianni A
    Blood Purif; 2020; 49(4):440-447. PubMed ID: 32050202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
    Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
    J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
    Covic AC; Floege J; Ketteler M; Sprague SM; Lisk L; Rakov V; Rastogi A
    Nephrol Dial Transplant; 2017 Aug; 32(8):1330-1338. PubMed ID: 27342579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
    Isaka Y; Fujii H; Tsujimoto Y; Teramukai S; Hamano T
    Clin Exp Nephrol; 2018 Aug; 22(4):967-972. PubMed ID: 29536389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Suzuki D; Ichie T; Hayashi H; Sugiura Y; Sugiyama T
    Pharmazie; 2017 Feb; 72(2):118-122. PubMed ID: 29441865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
    Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
    Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
    Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
    J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
    Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
    Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
    Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
    Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.